Weight-management and wellness businesses increasingly offer GLP-1 medications, hormone programs, peptides, compounded medications, and other therapies through clinics and telehealth platforms.
The regulatory analysis, however, involves much more than finding a provider willing to write prescriptions.
A compliant program should examine the entire process—from the patient’s first advertisement through evaluation, prescribing, dispensing, treatment, and follow-up.
Start With the Patient-Provider Relationship
Prescription programs require an appropriate clinical relationship.
Businesses should determine who evaluates the patient, whether that provider is properly licensed where the patient is located, what information is necessary before prescribing, and what follow-up is required.
When telehealth is involved, additional state-specific requirements may apply.
A questionnaire alone should not automatically be assumed sufficient simply because the interaction occurs online.
Understand the Medication Supply Chain
Wellness companies should know exactly where medications come from.
That analysis becomes particularly important with compounded medications.
Depending on the arrangement, medications may come from traditional pharmacies, compounding pharmacies operating under different federal frameworks, or other sources subject to distinct regulatory requirements.
The business should understand which entity dispenses the medication, whether medications are patient-specific, where products are shipped, how prescriptions are transmitted, and whether the pharmacy is appropriately authorized in the applicable jurisdiction.
Pharmacy Relationships Need Careful Structuring
A medical practice may develop relationships with pharmacies to make treatment more convenient for patients.
The financial relationship deserves separate analysis.
For example, arrangements under which a practice, MSO, marketer, or other company receives compensation based on prescriptions generated or patients directed to a pharmacy can raise fraud-and-abuse, fee-splitting, patient-brokering, or other regulatory concerns depending on the circumstances.
Calling a payment a “marketing fee” or “management fee” does not determine its legality.
The underlying relationship matters.
Peptides and Emerging Therapies Require Additional Attention
“Peptide therapy” is not a single regulatory category.
Different products can have very different regulatory statuses. Businesses should understand what substance is being offered, its source, its intended use, how it is marketed, and whether it may lawfully be prescribed, compounded, distributed, or administered for that purpose.
Products marketed as being for “research use only” create a particularly important distinction. A product’s availability for research purposes does not necessarily authorize its use as a medication for treating patients.
Marketing Should Match the Medicine
Advertising is another part of the compliance structure.
Statements concerning weight loss, anti-aging, hormone optimization, regenerative benefits, or other outcomes should be reviewed in the context of the actual treatment being offered and the evidence supporting the claims.
Businesses should also be careful not to allow marketing personnel to effectively determine clinical eligibility before an appropriate provider evaluates the patient.
Build the Program From End to End
A wellness program should connect clinical protocols, provider agreements, pharmacy relationships, patient consents, telehealth procedures, privacy documentation, marketing practices, and payment arrangements.
Apex Health Law works with medical practices, wellness companies, telehealth platforms, and MSOs to evaluate these relationships as part of the broader healthcare business model.
The goal is not simply to determine whether a particular medication can be offered. It is to determine whether the entire program has been structured appropriately.
This article is provided for general informational purposes only and does not constitute legal advice.




